" Interim results from the study revealed that the combination of ARRY-520 and Kyprolis showed a disease control rate of 82% along with a clinical benefit rate of 53%. The results further revealed that the combination was well tolerated with no serious side effects."
Also, please take note, ONXX Kyprolis is estimated to be a 2BB product by 2020:
"We model for Kyprolis WW revenue of $2.1B in 2020"
Riddle me this, riddle me that, why is ONXX on the selling block?
"Kyprolis, a blood-cancer treatment, is the “crown jewel” in this deal. The drug, already on the market, is expected to hit blockbuster level with sales of more than $1 billion per year. Kyprolis is wholly-owned by Onyx, a somewhat rare occurrence for a promising treatment on the market. Stifel estimated the Amgen bid valued Kyprolis at over $6 billion and estimate the sales could peak at $2.75 billion."
'MULTIPLE MYELOMA DRUG MARKET WILL REACH $9.9 BILLION IN 2015' PREDICTS VISIONGAIN REPORT"
This is what ONXX flagship targets and hence why ONXX is so valued. What I find particularly interesting is the following:
"James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx’s Kyprolis and Celgene’s Actimid. Both of these have advantages over current drugs, but they’re basically incremental improvements on what we already have – proteasome inhibitors and immunomodulators."
Incremental improvements? ARRY is also an incremental improvement when combined with ONXX Kyprolis...